Australia To Consider New Drug Price Caps In Next Year’s Budget
This article was originally published in PharmAsia News
Executive SummaryAustralia's federal government plans to lower the caps on the price of the medicines it covers when it considers next year's budget later this year. Drug makers are being advised by the Health Ministry that the budget might go after company profits if the current practice of discounts and incentives to pharmacists to push drugs is not restrained. The discounts get passed on to the consumer, Minister Nicola Roxon said, and the government does not feel the Pharmaceutical Benefits Scheme should be propping up industry profits, particularly in the current economic climate. (Click here for more
You may also be interested in...
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.